Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Advanced Solid Tumours 5Squamous Cell Carcinoma of Head and Neck 3Solid Tumors 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Leukemia, Myeloid, Acute 2Glioblastoma 2Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Muscle Invasive Bladder Cancer 1Meningeal Carcinomatosis 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Laryngeal Neoplasms 1Head and Neck Neoplasms 1Gliosarcoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Carcinoma, Endometrioid 1Brain Neoplasms 1Blast Crisis 1Astrocytoma 1Advanced Solid Tumors 1Adenocarcinoma Of Esophagus 1

Interventions

Imatinib Mesylate 18Dasatinib 12Cyclophosphamide 11fludarabine phosphate 9nilotinib 8fludarabine 7Sirolimus 6ruxolitinib 5Tacrolimus 5Mycophenolic Acid 5Cytarabine 5Azacitidine 5Whole-Body Irradiation 4Ipilimumab 4Busulfan 4Bortezomib 4thymoglobulin 3bosutinib 3belinostat 3aldesleukin 3Specimen Handling 3Nivolumab 3Interleukin-2 3Granulocyte Colony-Stimulating Factor 3Clofarabine 3CTLA-4 Antigen 3Antilymphocyte Serum 3AP 1903 reagent 3zileuton 2tozasertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × adavosertib × Clear all
NCT02381548 2026-01-30

Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1 Terminated
20 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡